Biotron Limited (ASX:BIT)
Australia · Delayed Price · Currency is AUD 0.0020
-0.0005 (-20.00%)
Sep 3, 2026, 9:59 AM AEST
Biotron Revenue
In the fiscal year ending June 30, 2026, Biotron had annual revenue of 525.87K AUD, down -71.00%. Biotron had revenue of 525.87K in the half year ending June 30, 2026.
Revenue
525.87K
Revenue Growth
-71.00%
P/S Ratio
10.59
Revenue / Employee
175.29K
Employees
3
Market Cap
5.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 525.87K | -1.29M | -71.00% |
| Jun 30, 2025 | 1.81M | 168.51K | 10.24% |
| Jun 30, 2024 | 1.65M | 213.83K | 14.94% |
| Jun 30, 2023 | 1.43M | -127.24K | -8.16% |
| Jun 30, 2022 | 1.56M | 96.58K | 6.61% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Acrux | 6.58M |
| Tissue Repair | 2.99M |
| Vectus Biosystems | 2.77M |
| Cynata Therapeutics | 1.71M |
| Bio-Gene Technology | 1.08M |
| Nexalis Therapeutics | 1.07M |
| ReNerve | 510.36K |
| AdAlta | 404.25K |